

The Consumer Voice in Europe

# Pharma marketing, social media, and GLP-1RA medicines

#### Ancel·la Santos, Senior Health Policy Officer

1 July 2024 - EMA/HMA Multistakeholder workshop on shortages of Glucagon-Like Peptide-1 (GLP-1) receptor agonists



#### **BEUC** is proud of its members

























































































#### GROWING PUBLIC HEALTH PROBLEM

- Medicine shortages are common across countries
- Consumer surveys on shortages show negative impact on people's health and pockets (1)
  - Anxiety
  - Disease worsening
  - Side-effects from alternative treatments
  - Extra costs for consumers
- Pharmacists across the EU spend about 10 hours per week on average addressing shortages (2)

<sup>(1)</sup> Surveys conducted by BEUC members Altroconsumo (Italy), DECO (Portugal), OCU (Spain) and Test Achats/Test Aankoop as part of the Euroconsumers group, and by the Norwegian Consumer Council. In BEUC, 'Factsheet. Medicine shortages in EU: alarming survey results from some countries', 2022 <a href="https://www.beuc.eu/sites/default/files/publications/beuc-x-2022-008\_medicine\_shortages\_in\_eu-alarming\_survey\_results\_from\_some\_countries.pdf">https://www.beuc.eu/sites/default/files/publications/beuc-x-2022-008\_medicine\_shortages\_in\_eu-alarming\_survey\_results\_from\_some\_countries.pdf</a>


<sup>(2)</sup> PGEU, 'Medicine shortages report 2023', https://www.pgeu.eu/wp-content/uploads/2024/01/PGEU-Medicine-Shortages-Report-2023.pdf



#### **GLP-1 RECEPTOR AGONISTS**

- Long-lasting shortages
- Multifaceted problem
  - Supply related constraints
  - Demand increase
  - Off-label use
  - Falsified medicines

- Blockbusters
- (Social) media traction
- Pharma promotion



Soure: MediaRadar in Constantino AK and Capoot A, 'Healthy Returns: Weight loss, diabetes drug ad spending tops \$1 billion', CNBC, 3 April 2024 <a href="https://www.cnbc.com/2024/04/03/weight-loss-diabetes-drug-ad-spending-tops-1-billion.html">https://www.cnbc.com/2024/04/03/weight-loss-diabetes-drug-ad-spending-tops-1-billion.html</a>



## A WORD ON PHARMA MARKETING

- Pharma promotion associated with:
  - > More prescriptions; higher costs; lower prescribing quality (1-3)
- Stricter rules in the EU compared to the US, but...
- Reported concerns with disease awareness campaigns (4-5)
- Social media as an amplifier

<sup>(1)</sup> Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, et al., 'Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review'. PLoS Med, 7(10):e1000352., 2010.

<sup>(2)</sup> Fickweiler F, Fickweiler W, Urbach E., 'Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review'. BMJ Open. 2017'Sep 7;7(9):e016408

<sup>(3)</sup> Brax H, Fadlallah R, Al-Khaled L, et al., 'Association between physicians' interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis'. PLoS One. 2017 Apr 13;12(4):e0175493.

<sup>(4)</sup> Leonardo Alves T, Martins de Freitas AF, van Eijk MEC, et al., 'Compliance of disease awareness campaigns in printed Dutch media with national and international regulatory guidelines'. PLoS ONE, 9(9):e106599, 2014.

<sup>(5)</sup> Leonardo Alves, T, Poplavska, E, Mezinska, S, et al., 'Disease awareness campaigns in printed and online media in Latvia: cross-sectional study on consistency with WHO ethical criteria for medicinal drug promotion and European standards'. BMC Public Health. 2018; 18: 1322.




#### DISEASE AWARENESS CAMPAIGN EXAMPLES



Images taken from the campaign's website, 'It's bigger than me' accessed on 27 June 2024







Mobile phone snapshot from Facebook's timeline and campaign's website, December 2023




#### REFLECTIONS & WAY FORWARD

Voluntary industry's commitments are welcome but not enough

#### Regulatory action

- Medicine shortages: Require companies to cut down on marketing
- Revised EU pharma legislation:
  - Require all Member States to establish a system of prior vetting
  - o Introduce specific measures on pharma promotion on social media
  - Oblige companies to develop shortage prevention plans
  - Facilitate patient reporting on shortages
- Regulatory cooperation (Europe, global)
- Active monitoring by the authorities and enforcement





https://www.beuc.eu/sites/default/files/publications/BEUC-X-2023-093\_From\_influence\_to\_responsibility\_Time\_to\_regulate\_influencer-marketing.pdf



### **Bibliography**

Alves Leonardo, T, Lexchin, and J, Mintzes, B., 'Medicines Information and the Regulation of the Promotion of Pharmaceuticals, Sci Eng Ethics', 2018, doi: 10.1007/s11948-018-0041-5

BBC News Mundo, Redacción 'El aumento de las versiones falsificadas de Ozempic, la inyección de moda para bajar de peso, y los riesgos de tomarlas', 27 October 2023

Buntz, B. 'Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape', Drug Discovery & Development, 21 May 2024

European Medicines Agency, 'EU actions to tackle shortages of GLP-1 receptor agonists', 26 June 2024

European Medicines Agency, 'EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens', 18 October 2023

Fresques, H. 'Doctors Prescribe More of a Drug If They Receive Money from a Pharma Company Tied to It'. Dollars for Doctors, ProPublica, 20 December 2019

Hart R. 'Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy', Forbes, 2 May 2024

Missakian, N. 'Novo Nordisk casts Queen Latifah in TV-themed awareness campaign for obesity', 1 November 2021

Satija B and Wingrove, P., 'Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by \$2 billion', Reuters, 30 April 2024

Test Achats Santé, 'La pénurie d'Ozempic est principalment la faute de son fabricant Novo Nordisk', 14 November 2023

World Health Organization, 'WHO issues warning on falsified medicines used for diabetes treatment and weight loss', 20 June 2024

Mulinari, S, Pashley, D, and Ozieranski P., 'Patterns of company misconduct, recidivism, and complaint resolution delays: A temporal analysis of UK pharmaceutical industry self-regulation within the European context', Regulation & Governance, 2024, doi:10.1111/rego.12609



The Consumer Voice in Europe

# Thank you for your attention

www.beuc.eu @beuc

